Skip to main content

Table 1 Clinical characteristics of the study population

From: Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain

 

T2DM (n = 50)

Control (n = 32)

p value

Age (year)

55 ± 7

54 ± 6

0.483

Male (n, %)

28 (56)

17 (53.1)

0.799

BMI (kg/m2)

24.7 ± 3.7

23.7 ± 2.3

0.165

Diabetes duration (year)

10 (6–13)

–

–

HR (bpm)

69 ± 9

66 ± 9

0.128

SBP (mmHg)

128 ± 14

124 ± 10

0.215

DBP (mmHg)

78 ± 10

75 ± 8

0.159

Hypertension (n, %)

19 (38)

–

–

Diabetic complication (n, %)

 Retinopathy

14 (28)

–

–

 Neuropathy

10 (20)

–

–

 Peripheral vascular disease

6 (12)

–

–

 Hematocrit (%)

39.3 ± 4.1

41.7 ± 3.7

0.009*

 BUN (mmol/L)

5.3 ± 1.6

–

–

 Creatinine (μmol/L)

68.9 ± 14.7

–

–

 Total cholesterol (mmol/L)

4.4 ± 1.0

–

–

 Triglycerides (mmol/L)

1.62 ± 1.2

–

–

 HDL-C (mmol/L)

1.3 ± 0.3

–

–

 LDL-C (mmol/L)

2.5 ± 0.7

–

–

 FPG (mmol/L)

8.3 ± 3.3

–

–

 Hemoglobin A1C (%)

8.9 ± 2.3

–

–

Hypoglycemic medication, n (%)

 Insulin

24 (48)

–

–

 Metformin

22 (44)

–

–

 Sulfonylurea

10 (20)

–

–

Other medication, n (%)

 Statin

21 (42)

–

–

 Aspirin

16 (32)

–

–

 ACEI

20 (40)

–

–

 Diuretics

5 (10)

–

–

 Calcium channel blockers

5 (10)

–

–

 β-blockers

9 (18)

–

–

  1. All data are expressed as the means ± SDs, percentages (numbers of participants), or medians (interquartile ranges) as appropriate
  2. DM diabetes mellitus, BMI body mass index, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea nitrogen, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FPG fasting plasma glucose, ACEI angiotensin-converting enzyme inhibitor
  3. * p < 0.05 between groups